These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 3207617)

  • 41. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 42. L-arginine therapy in Raynaud's phenomenon?
    Agostoni A; Marasini B; Biondi ML; Bassani C; Cazzaniga A; Bottasso B; Cugno M
    Int J Clin Lab Res; 1991; 21(2):202-3. PubMed ID: 1815764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Raynaud's phenomenon : Practical management].
    Drerup C; Maier A; Ehrchen J
    Z Rheumatol; 2019 Dec; 78(10):967-978. PubMed ID: 31712897
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased oesophageal blood flow in patients with Raynaud's phenomenon.
    Belch JJ; Land D; Park RH; McKillop JH; MacKenzie JF
    Br J Rheumatol; 1988 Dec; 27(6):426-30. PubMed ID: 3203185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cold hypersenstivity in Raynaud's phenomenon.
    Jamieson GG; Ludbrook J; Wilson A
    Circulation; 1971 Aug; 44(2):254-64. PubMed ID: 4327362
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of the cold pressor test on diffusing capacity. Comparison of normal subjects and those with Raynaud's disease and progressive systemic sclerosis.
    Miller MJ
    Chest; 1983 Sep; 84(3):264-6. PubMed ID: 6884100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Raynaud's phenomenon. Photoelectric plethysmography of the fingers of persons with and without Raynaud's phenomenon during cooling and warming up.
    Wouda AA
    Acta Med Scand; 1977; 201(6):519-23. PubMed ID: 878907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blood flow changes with naftidrofuryl in systemic sclerosis and Raynaud's phenomenon.
    Gaylarde PM; Tan OT; Sarkany I
    Br J Dermatol; 1980 Jan; 102(1):7-10. PubMed ID: 7378283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
    Pamuk GE; Turgut B; Pamuk ON; Vural O; Demir M; Cakir N
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Points to consider-Raynaud's phenomenon in systemic sclerosis.
    Cutolo M; Smith V; Furst DE; Khanna D; Herrick AL
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v45-v48. PubMed ID: 28992170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis.
    Lekakis J; Papamichael C; Mavrikakis M; Voutsas A; Stamatelopoulos S
    Am J Cardiol; 1998 Dec; 82(12):1555-7, A8. PubMed ID: 9874070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon.
    Khan F; Coffman JD
    Circulation; 1994 Mar; 89(3):1183-8. PubMed ID: 8124805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasmapheresis in Raynaud's phenomenon in systemic sclerosis: a microcirculatory study.
    Jacobs MJ; Jörning PJ; Van Rhede van der Kloot EJ; Kitslaar PJ; Lemmens HA; Slaaf DW; Reneman RS
    Int J Microcirc Clin Exp; 1991 Feb; 10(1):1-11. PubMed ID: 2019479
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis.
    Galluccio F; Matucci-Cerinic M
    Autoimmun Rev; 2011 Mar; 10(5):241-3. PubMed ID: 20863907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.